Table 1 Inhibition of cellular proliferation by WEHI-7326: a panel of cancer cell lines.

From: Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Cell line

Type of cancer

IC50 (nM)*

LoVo

Colon carcinoma

42.2 ± 9.9

SW480

Colon carcinoma

39.5 ± 4.1

LIM1899

Colon carcinoma

31.3 ± 2.6

LIM 2537

Colon carcinoma

58.9 ± 7.5

MDA-MB-231

Breast carcinoma

24.4 ± 3.1

PC3

Prostate carcinoma

48.9 ± 11.1

H1437

Non-small cell lung carcinoma

29.7 ± 10.8

U87MGΔ2–7

Glioblastoma expressing activated EGFR

6.1 ± 1.6

CEM

Leukemia, acute lymphoblastic

3.99 ± 0.04

CEM dEpoB30

Leukemia (taxane resistant, β-tubulin mutation)

1.67 ± 0.04

CEM dEpoB300

Leukemia (taxane resistant, β-tubulin mutation)

6.51 ± 0.08

  1. *72 h viability assay using CellTiterGlo or Alamar Blue (leukemia cell lines) reagent. IC50 values are the mean of 3 independent experiments run in duplicates shown with SEM.
Back to article page